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INTRODUCTION
Glioblastoma (GBM), a World Health
Organization (WHO) grade IV astrocy-
toma, is the most common and diffi-
cult primary brain tumor to treat (Braun
et al., 2012). Even when detected early,
the median survival rate for patients is
12–15 months (Adamson et al., 2009;
Johnson and O’Neill, 2012). The chal-
lenge in treating GBM arises from its resis-
tance to therapies such as radiotherapy
and chemotherapy. GBM tumors are quite
infiltrative into the surrounding normal
brain permitting tumors to recur locally in
the majority of patients.
The current standard of care treatment
for GBM involves surgery and radiation,
with concurrent and adjuvant chemother-
apy (Stupp et al., 2005). Surgery permits
the bulk of a GBM tumor to be removed
in most cases. All patients have resid-
ual tumor cells residing away from the
resection cavity that eventually lead to
local tumor recurrence and the demise
of the majority of patients (Hou et al.,
2006). The infiltrating GBM cells reside
centimeters away from the main tumor
mass in normal brain making it diffi-
cult for complete surgical removal (Kim
et al., 2014). Chemotherapy and radio-
therapy of patients after surgery attempts
to target these cells to prolong overall
patient survival. The blood brain barrier
(BBB) represents another challenge to the
treatment of GBM tumors by preventing
the accumulation of most chemothera-
peutics into the brain to target the infil-
trative cancer cells (Salazar et al., 1976;
Bidros and Vogelbaum, 2009). Surgery
and adjuvant therapies pose risks to the
patient such as neurologic deficits and
systemic toxicities. Known side effects of
radiation therapy with chemotherapy for
brain tumors include chronic fatigue, nau-
sea, and cognitive deficits (Loehrer et al.,
2011).
The BBB remains a formidable
challenge in the treatment of GBM and
malignant brain tumors. Its selective
permeability is due to the presence of
specialized endothelial cells, astrocytes,
pericytes, and neuronal terminals (Tajes
et al., 2014). The semi-permeable mem-
brane that comprises the BBB prevents
sufficient exposure of tumors to most
chemotherapeutic drugs that are com-
monly used to fight tumor progression
(Liu et al., 2010). Local disruption of the
BBB is found within GBM tumors. The
tumor vessels in GBM tumors are abnor-
mal both structurally and functionally
(Batchelor et al., 2007). The abnormal
tumor vessels further impair delivery
of therapeutics and create a hypoxic
microenvironment that can reduce the
effectiveness of radiation and chemother-
apy. Antiangiogenic therapy attempts to
normalize the tumor vasculature and
improve the tumor microenvironment
(Jain, 2001, 2005). Outside of the main
tumor mass, the BBB is intact where brain
cancer cells infiltrate into the surrounding
normal brain. The oral chemotherapy
agent, temozolomide (Temodar), can
penetrate the BBB and has resulted in
prolongation of overall survival patient
survival by several months (Stupp et al.,
2005).
The challenges associated with the
treatment of GBM tumors require novel
approaches for a greater impact on patient
survival and quality of life for patients.
MAGNETIC NANOPARTICLES (MNPs)
MNPs are most commonly comprised of
ferromagnetic iron-oxide (Fe3O4). They
are invisible to the naked eye, typi-
cally measuring 1–100 nm in diameter
(Sandhiya et al., 2009). MNPs can be
designed to target cancer by modification
of their surface with the addition of a pep-
tide or antibody specific to cancer cells
(Hadjipanayis et al., 2010). For biomedi-
cal applications, they can deliver targeted
therapy to specific regions of the body.
MNPs can be administered into the blood
stream systemically and directed to a target
with application of an external magnetic
field (Pankhurst et al., 2003). Particles can
be engineered to carry a drug, which can
be released once the particles reach their
target. In vivo experiments have shown
the effects of MNPs within a magnetic
field on glioma cells lasting up to 100min
postexposure (Braun et al., 2012). In a
separate study with rabbits, intravenous
injection of specially designed MNPs and
subsequent exposure to an external mag-
netic field resulted in permanent remis-
sion of squamous cell carcinoma tumors
(Chertok et al., 2008). While intravenous
administration is feasible with tumors in
other parts of the body, the BBB remains a
formidable challenge for systemic delivery
of agents for treatment of brain tumors.
For the treatment of patients with GBMs,
direct intratumoral delivery provides the
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greatest concentration of therapeutic while
minimizing systemic toxicities.
MRI CONTRAST ENHANCEMENT OF BRAIN
TUMORS
MNPs also serve as a powerful aid for the
imaging of brain tumors. Their inherent
ferromagnetic qualities provide sensitive
contrast enhancement with MR imaging
(Liu et al., 2010). Accumulation of MNPs
in brain tumors appears as a hypointen-
sity on T2-weighted imaging including
gradient echo imaging (Na et al., 2007).
FunctionalizedMNPs can be engineered to
target brain cancer cells which can in turn
be identified with MR imaging. For stan-
dard visualization of tumors, MNPs can
provide more sensitive imaging of tumors
when used as a contrast agent for MRI
(Kumar et al., 2010).
Ultrasmall superparamagnetic iron
oxide nanoparticles (USPIONPs), a sub-
class of superparamagnetic MNPs, are the
most effective types of MNPs that can be
used for imaging purposes (Thorek et al.,
2006). Their systemic half-life is two to
three times greater than standard MNPs
and are capable of being imaged by MRI
for longer periods of time (Varallyay et al.,
2002). In a recent study, it was noted that
USPIONPs can be used to detect areas
within brain tumors with increased blood
flow, which may be indicative of tumor
recurrence (Gambarota and Leenders,
2011). They can also be used to iden-
tify areas of pseudoprogression in brain
tumors after standard adjuvant therapies
such as radiotherapy and chemotherapy
(Gahramanov et al., 2011).
HYPERTHERMIA
Hyperthermia for the treatment of dif-
ferent cancers has been well described
in the past. Elevation of targeted areas
of the body above 40◦C can result in
cancer cell death (Wust et al., 2002).
In one study, researchers concluded that
even moderate hyperthermia at a temper-
ature around 45◦C was enough to cause
tumor cells to undergo apoptosis (Pu
et al., 2013). Furthermore, local or regional
hyperthermia can result in elevated blood
flow, which may assist in the delivery
of other treatments, such as chemother-
apy, which could result in a synergistic
antitumor effect (Kampinga, 2006; Issels,
2008).
While local or regional hyperthermia
can be effective in treating cancer involv-
ing different parts of the body, treating
brain tumors is difficult due to the sur-
rounding skull (Jordan et al., 1999). Heat
applied to the head is shielded by the skull
which results in less than optimal temper-
ature increases in the brain. Temperature
elevation of the entire brain for pro-
longed periods of time would result in side
effects and toxicities to patients. To pro-
vide a more targeted hyperthermia effect
for brain tumors, MNPs may be delivered
intratumorally prior to treatment with
alternating magnetic fields. This process,
known as thermotherapy, aims to deliver a
greater hyperthermia effect locally to brain
tumors while minimizing heating of the
surrounding brain.
THERMOTHERAPY
Due to the side effects and toxicities of
subjecting the entire brain to hyperther-
mia for extended periods of time, local-
ized treatment is necessary for effective
brain tumor therapy. Direct implantation
of MNPs into brain tumors can bypass
the BBB and allow for a maximum hyper-
thermic effect provided in a targeted man-
ner Figure 1. Brain autopsies of two GBM
patients after MNP injection, confirmed
that the MNPs were retained within tumor
tissue after implantation (Van Landeghem
et al., 2009). Once injected into tumors,
MNPs are subjected to an alternating mag-
netic field (AMF) which produces heat
via the Brownian Néel relaxation process
(Thiesen and Jordan, 2008; Deissler et al.,
2014).
The localized hyperthermic effect,
known as thermotherapy, involves the
application of an alternating magnetic
field (Maier-Hauff et al., 2011) Figure 1.
When applying a magnetic field to the tar-
get area, the strength of the hyperthermic
treatment is dependent on a variety of fac-
tors including the strength of the AMF,
the size and concentration of the MNPs,
and the time in which the field is applied
to the tumor region (Yanase et al., 1997;
Guedes et al., 2004; Meenach et al., 2010).
Targeted treatment is necessary because
prolonged application of hyperthermia to
healthy tissue can result in unwanted side
effects and toxicities (Fajardo, 1984). In
order to minimize the risk of systemic tox-
icities, the hyperthermic treatment is only
applied for a brief period of time to allow
for the MNPs within the targeted region to
heat up and cause necrosis or death of the
cancer cells. In human patients with brain
tumors, it was determined that hyperther-
mia with temperatures from 42◦C to 49◦C
were safe and caused very few side effects
for the patient (Maier-Hauff et al., 2007).
Thermotherapy does induce the death
of malignant cells (Marcos-Campos et al.,
2011). When a MNP is subjected to
an alternating magnetic field, its internal
temperature increases. This heat is then
transferred locally to the abnormal cells
situated around the nanoparticles which
further results in tumor death (Fajardo,
1984). With thermotherapy, only the tar-
geted tumor region is exposed to increased
temperatures, resulting in localized necro-
sis. When clinicians studied the benefits
of using thermotherapy in conjunction
with radiotherapy in relapsed GBM, they
reported an overall survival of 13.4months
compared to just 6.2 months with radio-
therapy and Temozolomide alone (Maier-
Hauff et al., 2011). Current limitations
to the use of MNPs for thermotherapy
of brain tumor patients include the high
MNP concentration required to generate
hyperthermia precluding the use of MRI,
as well as the effective delivery of theMNPs
(Wankhede et al., 2012).
The decreased resistance to heat
observed in GBM cells is not as clearly
presented when conducting experiments
with in vitro samples (Issels, 2008). Cancer
cells that reside in tumors are more sus-
ceptible to damage from heat than cancer
cells that are in vitro (Rhee et al., 1990).
This contrasts heavily with the significant
difference in immunity that is observed
when experiments are conducted using
in vivo models. One explanation for this
difference is that the vascular network
within the tumor is abnormal which can
lead to areas that have a difference in pH
as well as decreased availability of oxygen
(Issels, 2008).
CONCLUSION
Thermotherapy involving the use of an
AMF in conjunction with MNPs has
proven to be an effective method for treat-
ing patients with GBM. Initial tests have
shown that MNPs have minimal toxic-
ities to patients, though further testing
must be done to confirm these findings
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FIGURE 1 | Local hyperthermia treatment of a patient with a malignant
brain tumor after implantation of MNPs. (A) The patient undergoes an
alternating magnetic field (AMF) session (shown in yellow) for generation of
local hyperthermia in the region of the tumor. (B) Oscillation of the MNPs
(shown in yellow) within and adjacent to the tumor cells provides the
therapeutic hyperthermia (thermotherapy) effect. (C) Local implantation of
the MNPs within and adjacent to the brain tumor provides a targeted
therapeutic effect. (D) Brain tumor cells shown infiltrating normal brain may
be more susceptible to the effects of local hyperthermia by greater MNP
intracellular uptake and sensitivity to temperature changes.
(Mahmoudi et al., 2012). Much like other
methods that are used to combat GBM,
MNPs do not serve as a cure on their own;
they have shown to be most effective when
used as an adjuvant therapy with other
treatment modalities. Combining frac-
tionated radiotherapy with thermotherapy
has shown a survival advantage in patients
with relapsed GBM (Maier-Hauff et al.,
2011).
With further research, scientists can
bioengineer multitasking MNPs that can
be used for imaging, drug delivery, and
localized thermotherapy (Hadjipanayis
et al., 2013). Better targeting of MNPs may
provide more effective treatment of GBM.
The bioconjugation of drugs, monoclonal
antibodies, or peptides specific to cancer
cells will improve targeting. MNPs appear
to be well tolerated when delivered directly
into the human brain with few side effects
associated with them. Further testing of
MNPs with standard of care chemother-
apy, such as temozolomide, needs to be
completed in patients with malignant
brain tumors. MNPs will likely assume
a larger role in brain cancer treatment,
with other adjuvant therapies being used
to complement magnetic nanoparticles
(Kim et al., 2014).
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